Please assess the completion status of the following clinical trial:

Trial Title: Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk Hemoglobinopathies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion:~* Patients with a haploidentical related HLA donor and hemoglobin SS, hemoglobin SC, or hemoglobin Sb0/+ thalassemia and at least one of the following conditions:~  1. previous central nervous system vaso-occlusive episode with or without residual neurologic findings;~ 2. frequent painful vaso-occlusive episodes which significantly interfere with normal life activities and which necessitate chronic transfusion therapy;~ 3. recurrent SCD chest syndrome events, which necessitate chronic transfusion therapy;~ 4. severe anemia, which prevents acceptable quality of life and necessitates chronic transfusion therapy.~* Patients with a haploidentical related HLA donor and homozygous b0/+ thalassemia or severe variants of b0/+ thalassemia and require chronic transfusion therapy.~* Women of childbearing potential must have a negative pregnancy test.~* Between the ages of birth and 65 years.~Exclusion:~* HLA identical or 5/6 HLA matched sibling donor~* Biopsy proven chronic active hepatitis or portal fibrosis.~* SCD chronic lung disease \> stage 3 Severe renal dysfunction defined as creatinine clearance \<40 ml/min/1.73 M2.~* Severe cardiac dysfunction defined as shortening fraction \<25%.~* HIV infection.~* Unspecified chronic toxicity serious enough to detrimentally affect the patient's capacity to tolerate Stem Cell Transplant.~* Patient or guardian(s) unable to understand the nature and risks inherent in the stem cell transplant process.~* Pregnant or lactating females and those unwilling to use acceptable contraception.

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).